# Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries

> **NCT03557255** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute, Egypt** · enrollment: 60 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Levosimendan
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT03557255
- **Lead sponsor:** National Cancer Institute, Egypt
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2018-02-01
- **Final completion:** 2018-04-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03557255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03557255, "Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03557255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*